메뉴 건너뛰기




Volumn 31, Issue 2, 2011, Pages 91-94

Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in korean patients with acute coronary syndrome

Author keywords

Acute coronary syndrome; Clopidogrel resistance; CYP2C19; Korean; Platelet inhibition

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

EID: 79955369135     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2011.31.2.91     Document Type: Article
Times cited : (19)

References (14)
  • 1
    • 68149180722 scopus 로고    scopus 로고
    • Recent developments in Clopidogrel pharmacology and their relation to clinical outcomes
    • Gurbel PA, Antonino MJ, Tantry US. Recent developments in Clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol 2009;5:989-1004.
    • (2009) Expert Opin Drug Metab Toxicol , vol.5 , pp. 989-1004
    • Gurbel, P.A.1    Antonino, M.J.2    Tantry, U.S.3
  • 3
    • 41249093357 scopus 로고    scopus 로고
    • At al. Adjusted Clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with Clopidogrel resistance: A multicenter randomized prospective study
    • Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, at al. Adjusted Clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with Clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-11.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 1404-1411
    • Bonello, L.1    Camoin-Jau, L.2    Arques, S.3    Boyer, C.4    Panagides, D.5    Wittenberg, O.6
  • 6
    • 35048825671 scopus 로고    scopus 로고
    • Platelet function testing and cardiovascular outcomes: Steps forward in identifying the best predictive measure
    • DOI 10.1160/TH07-08-0518
    • Angiolillo DJ and Alfonso F. Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost 2007;98:707-9. (Pubitemid 47555058)
    • (2007) Thrombosis and Haemostasis , vol.98 , Issue.4 , pp. 707-709
    • Angiolillo, D.J.1    Alfonso, F.2
  • 7
    • 77955416969 scopus 로고    scopus 로고
    • Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic Clopidogrel therapy
    • Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, at al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic Clopidogrel therapy. J Thromb Haemost 2010;8:1685-93.
    • (2010) J Thromb Haemost , vol.8 , pp. 1685-1693
    • Sibbing, D.1    Gebhard, D.2    Koch, W.3    Braun, S.4    Stegherr, J.5    Morath, T.6
  • 8
    • 67649370752 scopus 로고    scopus 로고
    • Relation of genetic polymorphisms in the cytochrome P450 gene with Clopidogrel resistance after drug-eluting stent implantation in Koreans
    • Lee JM, Park S, Shin DJ, Choi D, Shim CY, Ko YG, at al. Relation of genetic polymorphisms in the cytochrome P450 gene with Clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 2009;104:46-51.
    • (2009) Am J Cardiol , vol.104 , pp. 46-51
    • Lee, J.M.1    Park, S.2    Shin, D.J.3    Choi, D.4    Shim, C.Y.5    Ko, Y.G.6
  • 9
    • 58249135635 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 polymorphism in young patients treated with Clopidogrel after myocardial infarction: A cohort study
    • Collet JP, Hulot JS, Pena A, VTllard E, Esteve JB, Silvain J, at al. Cytochrome P450 2C19 polymorphism in young patients treated with Clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-17.
    • (2009) Lancet , vol.373 , pp. 309-317
    • Collet, J.P.1    Hulot, J.S.2    Pena, A.3    Vtllard, E.4    Esteve, J.B.5    Silvain, J.6
  • 10
    • 1242315475 scopus 로고    scopus 로고
    • Frequency of nonresponse antiplatelet activity of Clopidogrel during pretreatment for cardiac catheterization
    • Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of Clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004; 93:456-8.
    • (2004) Am J Cardiol , vol.93 , pp. 456-458
    • Mobley, J.E.1    Bresee, S.J.2    Wortham, D.C.3    Craft, R.M.4    Snider, C.C.5    Carroll, R.C.6
  • 13
    • 77949297362 scopus 로고    scopus 로고
    • Which platelet function test is suitable to monitor Clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogreL
    • Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, et al. Which platelet function test is suitable to monitor Clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogreL J Thromb Haemost 2010;8:482-8.
    • (2010) J Thromb Haemost , vol.8 , pp. 482-488
    • Bouman, H.J.1    Parlak, E.2    Van Werkum, J.W.3    Breet, N.J.4    Ten Cate, H.5    Hackeng, C.M.6
  • 14
    • 57849099154 scopus 로고    scopus 로고
    • Quantitative determination of Clopidogrel active metabolite in human plasma by LC-MS/MS
    • Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A. Quantitative determination of Clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm Biomed Anal 2008;48:1219-24.
    • (2008) J Pharm Biomed Anal , vol.48 , pp. 1219-1224
    • Takahashi, M.1    Pang, H.2    Kawabata, K.3    Farid, N.A.4    Kurihara, A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.